Events

Presenters include Karen Gallant, Deputy Executive Director of CARB-X. Few technologies have the potential to disrupt and eliminate infectious disease and viral infections– but gene editing, CRISPR in particular, is […]

Kevin Outterson, Executive Director of CARB-X, is participating in a special panel discussion titled "When antibiotics fail: An international conversation about the worrisome evidence of impact and what can be […]

Presenters include Kevin Outterson, Executive Director of CARB-X, and Erin Duffy, CARB-X Chief of Research and Development. The FDA, IDSA, NIAID and Pew are co-sponsoring this workshop to focus on […]

In this webinar our moderator Caroline Purslow (Nesta Challenges) will welcome three speakers. Till Bachmann (University of Edinburgh) will give an overview of recent advances in AMR diagnostics development. He will discuss: State of the art approaches for diagnosing infections and AMR Pipeline of promising tests Challenges of adoption Amrita Sukrity (SpotSense) will draw from […]

Speakers include Kevin Outterson, Executive Director of CARB-X. The rise of antimicrobial resistance and the corresponding lack of novel antibiotic development impacts the ability of physicians to provide appropriate care for patients. The greatest barriers to a robust antibiotic ecosystem are low return on investment (ROI) and limited market opportunities, in part due to payment […]

Moderator: Kevin Outterson, Executive Director, CARB-X, Professor of Law, Boston University Panel: Lars Rebien Sorensen, Chairman of the Novo Nordisk Foundation and Novo Holdings Jeremy Farrar, Director, Wellcome Trust Dr. Malin […]

In this webinar, the following aspects will be presented: What are the most common techniques used to measure the extent of the risk of selecting for resistance when using a novel direct-acting antibacterial. What are the advantages and limitations of these techniques? What are some techniques that may be used to understand the origins of […]

In this webinar, the following aspects will be presented: Discovery and early development of “non-traditional” antibacterial approaches is a noticeable trend in the pre-clinical global pipeline These approaches include anti-virulence strategies, microbiome-modifying therapies, phages and others such as nanoparticles, immunotherapy and drug-resistance modulation Some of these approaches require novel preclinical efficacy models to predict clinical […]

In this webinar, Alexander J. Lepak will review critical study elements that lead to robust preclinical PK/PD results in the murine model. Topics discussed will include: Understanding and embracing the inherent variability in many components of the murine model Demonstrating how to generate and interpret preclinical murine model PK/PD results The presentation will be followed […]

The Boston Area Antimicrobial Resistance Network Meeting, to be held on Friday, March 20th. BAARN2020 will be the 7th iteration of this flagship MSI event, bringing together our collective talents across academia and industry to address the persistent dilemma posed by antimicrobial resistant infection.   Talks will begin at 9 AM in the Northwest Labs […]